Dr. Frank Giles - CML - Chronic Myeloid Leukemia
Dr. Francis J. Giles is an internist in Chicago, Illinois. He received his medical degree from National University of Ireland, Galway and has been in practice for more than 20 years.
Extract of US News
ARTICLES
Follow-Up Data Support Long-Term Treatment-Free Remission After Stopping Frontline Nilotinib in Patients With Chronic-Phase CML
May 15, 2019, Asco Daily News
Quantification of BCR-ABL by digital PCR in samples with high copy numbers and rates of molecular responses (as defined by EUTOS) compared to those detected with standard quantitative real-time PCR.
2016, ASCO PUBS
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
December 3, 2015, Journal Blood
Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)
December 6, 2014, blood
Nilotinib is Superior to Imatinib as First-line Therapy of Chronic Myeloid Leukemia: The ENESTnd Study
2010, Medscape
Leading the way in battle on cancer
August 31, 2010, The Irish Times
Breakthrough towards leukaemia cure
November 23, 2009, Irish Independant
Nilotinib Yields High One-Year Survival in Accelerated- Phase Patients Resistant to Imatinib
November 25, 2007, Oncology Times
NBA star may be benefiting from CTRC cancer drug
November 17, 2009 , HSC News
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
May 28, 2009, Leukemia
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
June 15, 2006, The New England Journal of Medicine
Clone wars in CML
2006, Leukemia
Two New Agents Effective in Gleevec-Resistant CML
December 10, 2004, Taylor & Francis Online
Follow-Up Data Support Long-Term Treatment-Free Remission After Stopping Frontline Nilotinib in Patients With Chronic-Phase CML
May 15, 2019, Asco Daily News
Quantification of BCR-ABL by digital PCR in samples with high copy numbers and rates of molecular responses (as defined by EUTOS) compared to those detected with standard quantitative real-time PCR.
2016, ASCO PUBS
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
December 3, 2015, Journal Blood
Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)
December 6, 2014, blood
Nilotinib is Superior to Imatinib as First-line Therapy of Chronic Myeloid Leukemia: The ENESTnd Study
2010, Medscape
Leading the way in battle on cancer
August 31, 2010, The Irish Times
Breakthrough towards leukaemia cure
November 23, 2009, Irish Independant
Nilotinib Yields High One-Year Survival in Accelerated- Phase Patients Resistant to Imatinib
November 25, 2007, Oncology Times
NBA star may be benefiting from CTRC cancer drug
November 17, 2009 , HSC News
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
May 28, 2009, Leukemia
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
June 15, 2006, The New England Journal of Medicine
Clone wars in CML
2006, Leukemia
Two New Agents Effective in Gleevec-Resistant CML
December 10, 2004, Taylor & Francis Online